Invex Therapeutics Ltd (IXC.AX)
Invex Therapeutics Ltd operates in the Biotechnology industry of the Healthcare sector, headquartered in Subiaco, WA, AU. The stock last traded at $0.12, up 0.00% on the session, giving a market capitalisation of $8.6M. Its beta of 0.54 implies it has historically moved less than the broad market.
Invex Therapeutics Ltd is an Australian biopharmaceutical company dedicated to researching and developing innovative treatments for various neurological disorders. Their primary focus is Exenatide, a promising therapeutic agent aimed at neurological conditions linked to or resulting from elevated intracranial pressure, including idiopathic intracranial hypertension, acute stroke, and traumatic brain injury. Exenatide has successfully advanced through Phase II clinical trials. The company was founded in 2019 and operates from Perth, Australia.
Invex Therapeutics Ltd is most often compared with the following Healthcare names: